Registration Has Closed
Letter of Intent due September 3, 2021
The ALS Association’s Clinical Trials Awards program supports early-stage interventional clinical trials to discover new treatments and cures for amyotrophic lateral sclerosis (ALS).
The ALS Association Global Research Program leads the scientific community in finding effective treatments and cure for ALS, and a better life for people with ALS, their caregivers, and families. The ALS Association is the largest private philanthropic funder of ALS research worldwide, and our efforts have led to some of the most promising and significant advances in ALS research.
There is an urgent need for new and improved therapies for ALS, as there is still no cure. The Clinical Trials Awards Program is open to industry and academic investigators proposing to develop novel or repositioning approaches for ALS. The Association seeks applications for early- stage clinical trials and stimulate the field to develop therapeutics for ALS. The goal of the program is to de-risk early clinical trials exploring safety and biomarkers to attract follow-on funding and get programs ready for future development (e.g., The Healey ALS platform trial).
To view the full funding announcement, click here.
Scope/Type of Clinical Trials supported through CTA program
- Clinical Stage: Early to mid-phase (phase 1, phase 2a) clinical trials exploring safety or biomarkers to justify larger phase 2b studies including single ascending dose (and multiple ascending dose studies to assess safety/tolerability, brain penetration, target engagement studies in healthy subjects and/or people living with ALS.
- Trial population: Can include genetic or sporadic forms of ALS, health subjects, as well as asymptomatic carriers.
- Therapeutic approaches: Small molecule, genetic therapies, stem-cell approaches, peptides, antibodies, antisense oligonucleotides, and others.
- Please Note: Non-pharmacological or surgical interventions are not considered appropriate for this RFA. Observational trials or natural history studies are not considered appropriate for this RFA
Funding and Eligibility
- The maximum period performance is three (3) years. Applicant could propose a 2-year or a 3-year project.
- Budgets for direct and indirect costs up to $1,000,000 per project may be requested.
- For a 2-year project – Year 1: $500,000; Year 2: $500,000
- For a 3-year project – Year 1: $500,000; Year 2: $250,000; $Year 3: $250,000
- Letter of Intent Due Date, if applicable: September 3, 2021, 5 p.m. US ET
- Full Applications Invites sent out: September 17, 2021
- Full Application Due Date (by invite only): November 8, 2021, 5 p.m. US ET
- Anticipated Award Decision: December 2021
- Grant Contracting: December 2021/January 2022*
*Note: The start date should be prior to January 31, 2022.
To Register for a proposalCENTRAL account, create a new Letter of Intent or to access an existing saved Letter of Intent, please visit: https://proposalcentral.com/
User Guides for proposalCENTRAL:
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Submit general questions and other related correspondence to [email protected].